All Cancer Type | Bladder | Breast | Cervix | Colorectal |
Esophagus | Head & Neck | Liver | Lung | Nasopharynx |
Pancreas | Prostate | Sarcoma | Stomach | Others |
Institution | Study Title | |
HKU | Rectal Adenocarcinoma (UW21-577)_A randomized study of neoadjuvant chemoradiotherapy with or without intensification with the FOLFOXIRI chemo-regimen for high-risk locally advanced rectal cancer |
Click for Details |
CUHK | Biliary Tract Cancer (BTC004) A Phase 3, Randomized, Double Blind Study of Pembrolizumab Plus Gemcitabine / Cisplatin versus Placebo Plus Gemcitabine / Cisplatin as First-Line Therapy in Participants with Advanced and/or Unresectable Biliary Tract Carcinoma |
Click for Details |
CUHK | Biliary Tract Cancer (BTC005) A Phase III Randomized, Double-Blind, Placebo-Controlled,Multi-Regional, International Study of Durvalumab in Combination withGemcitabine plus Cisplatin versus Placebo in Combination with Gemcitabine plusCisplatin for Patients with First-Line Advanced Biliary Tract Cancers (TOPAZ-1) |
Click for Details |
CUHK | Cancer Pain (SYM012)A pilot randomized open-labeled study comparing a structured titration method of immediate- and sustained-release oxycodone versus titration of investigators’ choice inadvanced cancer patients in Hong Kong |
Click for Details |
CUHK | Tenosynovial Giant Cell Tumor (TGC001) A Phase 3, Randomized, Placebo-controlled, Double-blind Study of Vimseltinib to Assess the Efficacy and Safety in Patients with Tenosynovial Giant Cell Tumor (MOTION) |
Click for Details |
CUHK | (GIS001) (Peak) A Phase 3 Randomized, Open-label, Multicenter Clinical Study of CGT9486+Sunitinib vs Sunitinib in Subjects with Locally Advanced, Unresectable, or Metastatic Gastrointestinal Stromal Tumors | Click for Details |